Tom Brokaw Being Treated for Multiple Myeloma
Longtime NBC News anchor Tom Brokaw has been diagnosed with multiple myeloma, according to a statement issued by Brokaw and NBC.
The author of "The Greatest Generation" and a current special NBC correspondent for the Winter Olympics, Brokaw was actually diagnosed over the summer and has been undergoing treatment at the Mayo Clinic.
For nearly 20 years, beginning in 1983, Brokaw hosted "NBC Nightly News with Tom Brokaw," becoming a trusted fixture in American households until he was replaced by Brian Williams in 2004.
NBC releases statement by Brokaw
"With the exceptional support of my family, medical team and friends, I am very optimistic about the future and look forward to continuing my life, my work and adventures still to come," Brokaw said in a statement released by NBC last night. "I remain the luckiest guy I know. I am very grateful for the interest in my condition, but I also hope everyone understands I wish to keep this a private matter."
There is no cure for multiple myeloma, a blood cancer that affects white blood cells in the bone marrow, although there are a few treatment options. Brokaw is 74.
You can learn more about Multiple Myeloma at CancerTreatment.net.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
